Literature DB >> 17888953

When is it best to repeat a 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography scan on patients with non-small cell lung cancer who have received neoadjuvant chemoradiotherapy?

Robert James Cerfolio1, Ayesha S Bryant.   

Abstract

BACKGROUND: The ideal time to repeat a 2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET)/computed tomography (CT) scan to accurately restage a patient after neoadjuvant chemoradiotherapy for non-small cell lung cancer (NSCLC) is unknown.
METHODS: This retrospective cohort study used a prospective database of patients who underwent neoadjuvant chemoradiotherapy, an initial and repeat FDG-PET/CT scan, and pathologic staging. The accuracy of the clinical stage suggested by repeat FDG-PET/CT was compared with the actual pathologic stage. Receiver operating characteristic (ROC) curves were used to determine when it was most accurate to repeat the FDG-PET/CT after the completion of the last dose of chest radiation.
RESULTS: The study comprised 109 patients, 93 of whom patients received 60 Gy (or higher) of radiotherapy. The median time to restaging was 24 days (range, 2 to 88 days). ROC analysis showed the optimal time to restage patients was 26 days for overall staging (area under the curve [AUC], 0.88) and 29 days for N2 restaging (AUC, 0.82). The accuracy for overall stage was 3 (38%) of 8 for patients for less than 10 days, 28 (72%) of 39 for patients between 11 and 20 days, 42 (88%) of 49 between 21 and 30 days, and 8 (62%) of 13 for 31 days or more. The accuracy for these time intervals for the restaging of the N2 lymph node was 50% (1/2) 40% (2/5), 88% (7/8), and 100% (3/3), respectively.
CONCLUSIONS: The optimal time to perform a repeat FDG-PET/CT scan after the completion of neoadjuvant chemotherapy and high-dose radiotherapy to maximize its accuracy for restaging patients with NSCLC is about 1 month after the last dose of radiation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17888953     DOI: 10.1016/j.athoracsur.2007.05.050

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  4 in total

1.  Multidisciplinary consensus statement on the clinical management of patients with stage III non-small cell lung cancer.

Authors:  M Majem; J Hernández-Hernández; F Hernando-Trancho; N Rodríguez de Dios; A Sotoca; J C Trujillo-Reyes; I Vollmer; R Delgado-Bolton; M Provencio
Journal:  Clin Transl Oncol       Date:  2019-06-06       Impact factor: 3.405

Review 2.  The use and misuse of positron emission tomography in lung cancer evaluation.

Authors:  Ching-Fei Chang; Afshin Rashtian; Michael K Gould
Journal:  Clin Chest Med       Date:  2011-12       Impact factor: 2.878

3.  Early PET/CT scans for assessing treatment responses of non-small cell lung cancer for SBRT boost: what to do with scans from multiple scanners.

Authors:  Ronald C McGarry; Jonathan Feddock; Partha Sinha; Gary Conrad; Brent J Shelton; Li Chen; Susanne M Arnold; John Rinehart
Journal:  J Radiosurg SBRT       Date:  2013

4.  Role of fluorodeoxyglucose-positron emission tomography in predicting the pathological response and prognosis after neoadjuvant chemoradiotherapy for locally advanced non-small-cell lung cancer.

Authors:  Masayuki Tanahashi; Eriko Suzuki; Naoko Yoshii; Takuya Watanabe; Hiroyuki Tsuchida; Shogo Yobita; Kensuke Iguchi; Suiha Uchiyama; Minori Nakamura
Journal:  Interact Cardiovasc Thorac Surg       Date:  2022-07-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.